SGL has demonstrated improvements in cognitive impairment by reducing microgliosis and astrogliosis, and by increasing nerve growth factor (NGF) levels in Aβ- and scopolamine-induced animal models of dementia [440]. This evidence concerns the gene NGF and Cognitive impairment.